NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
Clinical trial NCT01810016 · TERMINATED
Trial details
- NCT number
- NCT01810016
- Sponsor
- Ludwig Institute for Cancer Research
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-01-24
- Primary completion
- 2016-05-17
- Enrollment
- 8
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.